Poster Abstracts • OFID 2018:5 (Suppl 1) • S101 (i.e., MSSA), and (4) obtain echocardiogram. The ASP also provided education on antimicrobial therapy choices and optimization to clinical pharmacists and ID physicians. The hospital utilized Verigene Gram-positive blood culture nucleic acid test during both study periods and ASP review of SAB cases without an ID consult in the preintervention phase. The primary outcome was time to appropriate therapy defined as the time a positive blood culture was drawn to the time of first appropriate antibiotic administration.
Background. Overtreatment of asymptomatic bacteriuria (ASB) is a major challenge for antimicrobial stewardship (ASP). A February 2017 review of our health-system showed >50% of inpatients with a positive urine culture (PUC) were treated despite no urinary tract infection (UTI) symptoms or compelling indications (CI) [pregnancy or pending urologic procedure] . In Fall 2017, we piloted a multifaceted toolkit (MTK) to support an ASB educational campaign (EC) at 26 hospitals.
Methods. A MTK of flyers, a urinary testing algorithm, and narrated slides ( Figure 1 ) was distributed in Fall 2017 and implementation was customized by each hospital's ASP. Impact of EC on treatment of patients with no urinary symptoms (NUS) or altered mental status (AMS) alone were assessed retrospectively by sampling inpatient PUCs from February 1-28, 2018 in a manner identical to a pre-EC sample. Patients were excluded if: CI, age <18 years, neutropenic, or admitted on UTI therapy or with nephrolithiasis. Demographic, clinical, and laboratory data; UTI symptoms; microbiology results; and antimicrobial therapy received, were collected via an adapted CDC UTI assessment form. Each hospital was surveyed on MTK implementation. Background. The optimal timing of intervention to obtain significant effects with regard to reducing the consumption of antimicrobial agents or antimicrobial-resistant bacteria in facilities that lack the manpower to maintain an antimicrobial stewardship team (AST) is not well-known.
Methods. An observational retrospective study was performed at Fukuoka University Hospital between April 1, 2013 and March 31, 2016 to evaluate the optimal timing of intervention on appropriate antimicrobial therapy for specific antimicrobial agents, including broad-spectrum antimicrobial agents (piperacillin-tazobactam, carbapenems, fluoroquinolones) and anti-MRSA (vancomycin, teicoplanin, daptomycin, and linezolid) agents. In period 1, interventions were performed for patients using specific antimicrobial agents for >14 days. In period 2, interventions were performed for patients using anti-MRSA agents, and in period 3, interventions were performed for patients using any specific antimicrobial agents, regardless of the days of use, on a weekly basis. The effects on antimicrobial use, the antimicrobial-resistant bacteria, and the clinical outcomes among the three periods were compared.
Results. The AUDs of piperacillin-tazobactam and carbapenems decreased significantly (10.8 → 9.2 and 15.7 → 14.2; period 2 vs. period 3, P < 0.05). The rates of piperacillin-tazobactam, meropenem and levofloxacin resistance in Pseudomonas aeruginosa isolates decreased from 13.8%, 16.2%, 11.9% in period 1 to 10.4%, 8.7%, 6.5% in period 3, respectively. The annual costs of these antimicrobials decreased according to the period: period 1, US$ 1,080,000; period 2, US$ 944,000; and period 3, US$ 763,000 (period 3 vs. period 1, P <0.01). No recurrence was observed within 7 days after intervention and the mortality rate and length of stay did not change to a statistically significant extent in any of the study periods.
Conclusion. When interventions were performed once a week by an ASP team, accelerating the timing of intervention from patients with >14 days of use to all patients treated with the specific antimicrobial agents was significantly more effective for reducing the consumption of antimicrobials leading to reduction of the related costs and antimicrobial-resistant P. aeruginosa without compromising the patient outcomes. ; 1 health record (EHR) of patients discharged on oral antibiotics from the Medical Service at the William S Middleton VA Hospital for appropriateness of antibiotic choice and total duration of therapy. Depending on availability of team members, reviews occurred twice weekly and included patients discharged within the previous 4 days. If an antibiotic was felt to be inappropriate, the case was discussed with the prescribing service and/or pharmacist. Recommendations were documented in the form of a note placed in the EHR with an emphasis on education. These interventions were logged and information regarding prescribing team/provider, antibiotic, indication, and type of intervention was collected. Intervention types included (but were not limited to) antibiotic stop, change of antibiotic, dose, or duration, and laboratory recommendations. Results. Stewardship rounds evaluated 463 patients discharged on oral antibiotics from the Medical Service over 177 hospital days. Forty-one interventions were logged in 38 (8.2%) patients, i.e., approximately 1 intervention for every 12 patients discharged on oral antibiotics. The most common intervention type was antibiotic stop (49%), followed by a change in duration (15%). Interventions occurred most commonly in patients treated for COPD (27%), UTI (22%), and pneumonia (15%). Azithromycin (27%), cefpodoxime (12%), and trimethoprim-sulfamethoxazole (12%) were the antibiotics most frequently intervened upon.
Conclusion. Assessing postdischarge antibiotic therapy with feedback to prescribers is an additional area where Stewardship programs can focus to better optimize usage of antimicrobials.
Disclosures. Background. Inpatient antibiotics are estimated 30-50% inappropriate and novel antimicrobial stewardship (AS) strategies to engage prescribers are needed. The objective of this study was to describe the implementation of a customized antibiotic use and outcome report with family medicine (FAM) providers and the impact on prescribing behaviors for routine infections in hospitalized adults.
Methods. Single-center quasiexperiment before and after AS/FAM collaborative intervention. January-March 2017 Standard of Care: routine audit and feedback. FAM leadership worked with AS pharmacists to design reporting process. January-March 2018 Monthly Interventions: reports of antimicrobial use, appropriateness, harms; positive-deviance cases highlighting successful stewardship; education and survey of rotating FAM providers; handheld prescribing tools/guidelines. Consecutive admissions to the adult FAM ward with respiratory, urinary, and skin infections were evaluated. Primary endpoint: duration of optimal prescribing. Each day of therapy (DOT) was classified as optimal, suboptimal, unnecessary, or inappropriate. Antimicrobials were stratified by spectrum and propensity to cause harm. Secondary endpoints: use of broad-spectrum agents, appropriate duration of therapy, and safety.
Results. Adults (n = 150, 76 pre, 74 post) were similar in age, comorbid conditions, and antimicrobial indications (Figure 1 ). Following intervention, unnecessary antimicrobial days decreased from 2 to 0 days (P < 0.001) per patient, optimal therapy selection increased from 25% to 58% (P < 0.001). Narrow-spectrum agents increased from 41% to 59% (P = 0.05) while use of broader (52 vs. 48%) and extended spectrum agents (57 vs. 44%) were not significantly different in the cohort. Guideline concordant duration of therapy improved from 37% to 57% (P = 0.015). Concurrent unit-wide DOTs of broad and extended agents decreased (Figure 2) .
Conclusion. Reporting unit-specific antimicrobial use, harms and successes, without change in standard audit and feedback, improved antimicrobial prescribing and quality of care. These findings support the need to engage front-line providers like FAM in stewardship interventions and reporting.
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